“Anti-VEGF monotherapy will go down in medical history as a treatment model that was both insurmountable and unsustainable.” “It was insurmountable because of the historic gains that were seen in a disease, neovascular macular degeneration, that had miserable treatment results earlier. We went from essentially not being able to treat our patients at all and […]
https://www.retinalconsultantsaz.com/wp-content/uploads/2021/02/RCA-logo-transparent-1.png00retinalconsultantshttps://www.retinalconsultantsaz.com/wp-content/uploads/2021/02/RCA-logo-transparent-1.pngretinalconsultants2013-08-01 09:00:032013-08-01 09:00:03Anti-PDGF, anti-VEGF combination may be game changer in wet AMD treatment
To: Dr. Matthew Witmer & Retinal Consultants of Arizona While on my way to my eye appointment yesterday I happened to think of the many time folks have come up to my husband, a retired Marine, to thank him for his service. Then my thoughts turned to Dr. Witmer and the many hours of studying, […]
https://www.retinalconsultantsaz.com/wp-content/uploads/2021/02/RCA-logo-transparent-1.png00retinalconsultantshttps://www.retinalconsultantsaz.com/wp-content/uploads/2021/02/RCA-logo-transparent-1.pngretinalconsultants2012-12-08 09:00:112012-12-08 09:00:11Dr. Matthew Witmer: An Early Holiday Gift of Kindness
“Use of a novel anti-platelet-derived growth factor therapy in concert with ranibizumab resulted in a statistically significant improvement in visual outcome vs. ranibizumab monotherapy for the treatment of wet age-related macular degeneration, according to a press release from Ophthotech…” Retinal Consultants of AZ is committed to clinical research and the pursuit of new and improved […]
“The anti-platelet derived growth factor (PDGF) combination agent Fovista (Ophthotech Corp.) showed statistically significant superior efficacy over ranibizumab (Lucentis, Genentech) monotherapy for the treatment of wet AMD, according to the results of a phase 2b study, which were recently reported in an Ophthotech release…” Retinal Consultants of AZ is committed to clinical research and the […]
https://www.retinalconsultantsaz.com/wp-content/uploads/2021/02/RCA-logo-transparent-1.png00retinalconsultantshttps://www.retinalconsultantsaz.com/wp-content/uploads/2021/02/RCA-logo-transparent-1.pngretinalconsultants2012-06-13 09:00:412012-06-13 09:00:41Anti-PDGF Combination Agent More Effective Than Ranibizumab Monotherapy for Wet AMD
Anti-PDGF, anti-VEGF combination may be game changer in wet AMD treatment
/ AMD, Anti-PDGF, Anti-VEGF /by retinalconsultants“Anti-VEGF monotherapy will go down in medical history as a treatment model that was both insurmountable and unsustainable.” “It was insurmountable because of the historic gains that were seen in a disease, neovascular macular degeneration, that had miserable treatment results earlier. We went from essentially not being able to treat our patients at all and […]
Dr. Matthew Witmer: An Early Holiday Gift of Kindness
/ Uncategorized /by retinalconsultantsTo: Dr. Matthew Witmer & Retinal Consultants of Arizona While on my way to my eye appointment yesterday I happened to think of the many time folks have come up to my husband, a retired Marine, to thank him for his service. Then my thoughts turned to Dr. Witmer and the many hours of studying, […]
Combination therapy offers improved visual outcome compared with anti-VEGF monotherapy, trial finds
/ Uncategorized /by retinalconsultants“Use of a novel anti-platelet-derived growth factor therapy in concert with ranibizumab resulted in a statistically significant improvement in visual outcome vs. ranibizumab monotherapy for the treatment of wet age-related macular degeneration, according to a press release from Ophthotech…” Retinal Consultants of AZ is committed to clinical research and the pursuit of new and improved […]
Anti-PDGF Combination Agent More Effective Than Ranibizumab Monotherapy for Wet AMD
/ AMD, Anti-PDGF /by retinalconsultants“The anti-platelet derived growth factor (PDGF) combination agent Fovista (Ophthotech Corp.) showed statistically significant superior efficacy over ranibizumab (Lucentis, Genentech) monotherapy for the treatment of wet AMD, according to the results of a phase 2b study, which were recently reported in an Ophthotech release…” Retinal Consultants of AZ is committed to clinical research and the […]